More than 300 billion yuan of Chinese medicine market reshuffle tide, or will come!

"Pharmaceutical Network Market Analysis" recently, the State Health Insurance Administration revealed that the relevant departments have held a symposium in mid-July on biological products (including insulin) and Chinese medicine centralized procurement to listen to experts' opinions and suggestions, research and improve procurement policies in related fields, and promote the reform of procurement methods.
news, the industry generally believed that centralized procurement will expand the range of signals become clearer.
with the promotion of the volume procurement policy, the market of chinese medicine exceeding 300 billion yuan may officially enter the "shuffle" stage, the performance of Chinese medicine enterprises will also be affected by this.
, many places have been on the Chinese medicine procurement pilot.
For example, Qinghai Province in July published the public medical institutions drug belt procurement bargaining varieties catalog and Qinghai Province public hospital drug belt procurement of the proposed results show that thrombosis injection, injection with blood plug(freeze-dry), Magpie flat injection, blood plug to pass capsules and other large varieties are included in the centralized belt procurement of drugs catalog.
unique, Zhejiang Jinhua issued on June 8 "on the implementation of Jinhua City's second batch of drug belt procurement announcement" shows that 274 with volume procurement varieties, including 147 Chinese medicines (not including low-cost drugs) and 33 A Chinese medicine (including low-cost medicine), involving compound fishy herb enseging agent, oxen on the clear capsule, clearing the spirit particles, dredging detoxifying capsules, ginseng injection, strong dew, 100-ling capsules, six-flavored yellow pills, Ansin rehydration brain fluid and other common varieties.
Jinhua City, the volume of procurement clear procurement volume.
, for Chinese medicine, according to the previous year's usage statistics, listed in the monitoring directory of Chinese medicine according to not more than 80% of the previous year's use statistics.
From the "4 plus 7" drug collection pilot, "4 plus 7" expansion, the second batch of belt procurement to now open the tender for the third batch of band procurement, you can see that the price reduction of chemical drugs has become a major trend, then the purchase of Chinese medicine belt volume will be a big price reduction? Industry insiders said that from the chemical drug collection experience, under the collection, a significant reduction in drug prices will be inevitable.
is currently selected varieties appear in the country to low prices, it will trigger price reductions in the market, or will make the development of Chinese medicine enterprises more difficult.
, especially for those with more competitive chinese medicines, the relevant enterprises may be affected first.
meters of intranet data show that Chinese medicine covers 13 treatment categories, its central cerebrovascular disease drug for the Chinese medicine market sales of the top varieties, accounting for 35% of the market share, respiratory diseases accounted for 14.67 percent of drugs, skeletal musculoskeletal system medication accounted for 8.58 percent.
specifically, in 2019, the cumulative sales of TOP20, a Chinese medicine product in the terminals of China's public medical institutions, amounted to 60.2 billion yuan, and the sales of varieties exceeded 2 billion yuan, of which the annual sales of injectable thrombosis (freeze-dried) amounted to 62.2 billion yuan. 8.3 billion yuan, sales of dansan polyphenols for injection reached 4.135 billion yuan, sales of injection blood plug (freeze-dried) reached 3.928 billion yuan, Danhong injection 3.615 billion yuan.
with the purchase of Chinese medicine, the industry expects that the price of these large varieties of Chinese medicine injections will decline, which will have a greater impact on the performance.
In fact, in addition to the possible impact of harvesting, the Chinese medicine industry in recent years also faced the impact of health insurance policy adjustment, hospital rational drug policy gradually refined and other policies, market sales growth has gradually slowed down.
2019, sales of Chinese medicines in terminals of public medical institutions in China amounted to 283 billion yuan, with the first negative growth of 1.7%, according to data from china's Mienet.
in general, regardless of whether the purchase of Chinese medicine belt will be implemented in a large area of the country, Chinese medicine enterprises are facing greater challenges, what needs to be done is to accelerate the transformation and upgrading, improve competitiveness.
.